De Salir al Mercado ... Logicamente Benefiaria a l@s Pacientes de Primera Linea ... y las Farmaceuticas a las Que Más Perjdicaría Serían Roche y AstraZeneca .
... "" LOS RESULTADOS ACTUALES SON "" IMPRESIONANTES "" .
Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun Pharma USA Inc.
The Therapy is the first innovative monoclonal antibody developed by Shanghai Henlius Biotech,Inc. (stock code: 2696.HK) and Fosun Pharma USA has the exclusive right to commercialize SERPLULIMAB in the US upon regulatory approval. Serplulimab has the potential to be the world’s first anti-PD-1 mAb for the first-line treatment of SCLC and is the first asset as part of the partnership with Syneos Health . ...
*.- SERPLULIMAB Sería Rentable Tanto Para Tratar a los Pacientes ... Como Económicamente Hablando .
*.- Cuenta Ya con el Status de Orphan Drug en EEUU .
*.- De Ratificarse los Resultados ... Su Lanzamiento al Mercado Mundial Sería Rápido ... Principalmente en EEUU , EU Y CHINA .
MORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) .
(“Fosun Pharma USA“), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) .
As part of the partnership, Syneos Health will provide Full-Service Commercial support through its Syneos One® team for the launch of SERPLULIMAB, a novel anti-PD-1 antibody for extensive stage small cell lung cancer (ES-SCLC), in the US.
.jpeg)
.jpeg)
.jpeg)
.jpeg)
